What is already known about this topic?
On June 21, 2023, the Advisory Committee on Immunization Practices (ACIP) recommended that adults aged ≥60 years may receive a single dose of respiratory syncytial virus (RSV) vaccine, using shared clinical decision-making.
What is added by this report?
On June 26, 2024, ACIP voted to update these recommendations as follows: all adults aged ≥75 years and adults aged 60–74 years who are at increased risk for severe RSV disease should receive a single dose of RSV vaccine.
What are the implications for public health practice?
These updated recommendations are intended to maximize RSV vaccination coverage among persons most likely to benefit. Continued postlicensure monitoring will guide future recommendations.
- Recommendation
- Americas
- United States of America
- older adults
- RSV (Respiratory syncytial virus)
